figshare
Browse
1/1
4 files

Statistical Considerations in Demonstrating CMC Analytical Similarity for a Biosimilar Product

Version 49 2019-12-09, 13:02
Version 48 2019-04-05, 08:46
Version 47 2019-04-03, 09:34
Version 46 2019-04-03, 09:05
Version 45 2019-04-02, 15:15
Version 44 2019-04-02, 14:45
Version 43 2019-04-02, 13:26
Version 42 2019-04-02, 09:37
Version 41 2019-04-01, 11:44
Version 40 2019-04-01, 11:27
Version 39 2019-04-01, 08:26
Version 38 2019-04-01, 08:16
Version 37 2019-01-03, 09:26
Version 36 2019-01-03, 09:11
Version 35 2018-12-18, 13:03
Version 34 2018-12-18, 12:46
Version 33 2018-12-10, 13:47
Version 32 2018-12-10, 11:56
Version 31 2018-12-06, 14:00
Version 30 2018-12-06, 13:42
dataset
posted on 2019-12-09, 13:02 authored by Richard K. Burdick, Neal Thomas, Aili Cheng

Demonstration of analytical similarity between a reference product and a biosimilar product is required as part of the biosimilarity approval process. A statistical two one-sided test (TOST) based on the difference of means proposed in the literature and recommended by the FDA for Tier 1 quality attributes is demonstrated to have a type I error rate greater than the specified level, which cannot be corrected by increasing sample size. In this paper, an alternative TOST based on the effect size is demonstrated to maintain the desired type I error rate, and in some situations, provide greater power than the TOST based on the mean difference. Results are demonstrated both analytically and with computer simulations. An example with calculations is provided in the paper.

History

Usage metrics

    Statistics in Biopharmaceutical Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC